TIDMCRX

Cyprotex PLC

04 October 2011

4 October 2011

Cyprotex Launches Breakthrough Genomic ADME Service (gADME(TM) )

New Service Provides Understanding of Genetic Variations on Drug Response

Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today announces the launch of its new Genomic ADME service, making Cyprotex the pioneering discovery-focused ADME Tox contract research organisation providing drug researchers with actionable data about genomic differences in drug response at the early stages of drug development.

The new service, named gADME(TM), enables drug developers to identify which enzymes play a role in the metabolism of their drugs, to understand the impact of genetic polymorphisms on that metabolism, and to devise dose adjustment strategies. This gives drug developers the opportunity to substantially improve patient care through identifying and compensating for variability in patient drug response, and enabling personalised dose regimens.

Cyprotex's gADME(TM) service combines genomics with ADME to predict inter-individual variability in human pharmacokinetics. The technology utilises a panel of proprietary enzyme systems providing a comprehensive range of drug metabolising enzymes, including genetic variants of these enzymes.

Genetic polymorphisms (variants) in drug metabolism greatly affect plasma levels in vivo, making them one of the major causes of both adverse drug reactions and of lack of drug efficacy in humans. The most commonly reported genetic polymorphisms in drug metabolism are those for the cytochrome P450 enzymes (CYPs), a diverse and key group of enzymes. Expression of these enzymes and the number of active and inactive alleles differ significantly as a function of ethnicity, resulting in sometimes large variations in drug plasma levels between individuals of different ethnic origins.

Until now, such variances in drug plasma levels has meant that drug developers have to discard potential drugs whose metabolism is substantially dependent on these polymorphic enzymes and drugs that could have benefited one or more ethnic groups are not being pursued because of adverse effects or lack of efficacy within other ethnic groups.

Dr. Katya Tsaioun, Cyprotex's Chief Scientific Officer, comments on the launch of gADME(TM): "Many potentially valuable drugs are being discarded in early development because they are metabolised by polymorphic CYPs, which puts the drugs at risk of excessively variable drug plasma levels among patients. Cyprotex's gADME(TM) service allows drug developers to understand the effect of genetic polymorphisms on drug toxicity and efficacy. This understanding will enable drug developers to identify appropriate dose adjustment strategies personalised for an individual's genotype. This in turn can enable existing therapies to be repositioned, and successful development of drugs that would have heretofore been discarded."

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: "The launch of gADME(TM) represents a significant milestone in Cyprotex's scientific evolution. In the past year Cyprotex diversified into proprietary services spearheaded by our predictive toxicology technology CellCiphr(TM) and now gADME(TM) for genetic ADME. Last year Cyprotex entered the in vitro toxicology market and we can now offer a large portfolio of predictive toxicology services."

For further information:

 
 Cyprotex PLC                                       Tel: +44 (0) 1625 505 
                                                     100 
 Dr Anthony Baxter, Chief Executive Officer         ir@cyprotex.com 
  John Dootson, Chief Financial Officer              www.cyprotex.com 
  Mark Warburton, Chief Operating Officer and 
  Legal Counsel 
 
 Singer Capital Markets Limited (broker to          Tel: +44 (0) 203 205 
 Cyprotex)                                           7500 
 Shaun Dobson                                       shaun.dobson@singercm.com 
  Claes Spang                                        claes.spang@singercm.com 
                                                     www.singercm.com 
 
 FTI Consulting                                     Tel: +44 (0) 20 7831 
                                                     3113 
 Ben Brewerton                                      cyprotex@fticonsulting.com 
  Ben Atwell                                         www.fticonsulting.com 
  Mo Noonan

Notes to Editors:

Cyprotex PLC

Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGUBDGUSGBGBS

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cyprotex Charts.
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cyprotex Charts.